MCID: TNC001
MIFTS: 35

Tinea Cruris

Categories: Infectious diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Tinea Cruris

MalaCards integrated aliases for Tinea Cruris:

Name: Tinea Cruris 11 14 71 75 31
Dermatophytosis of Groin and Perianal Area 11
Dermatophytosis of Groin & Perianal Area 11
Tinea of Perianal Region 71
Dhobie Itch 11

Classifications:



External Ids:

Disease Ontology 11 DOID:11917
ICD9CM 34 110.3
NCIt 49 C34535
SNOMED-CT 68 59089002
ICD10 31 B35.6
UMLS 71 C0011638 C0040253 C1384589

Summaries for Tinea Cruris

Disease Ontology: 11 A dermatophytosis that results in fungal skin infection located in groin, located in perineum, or located in perianal region, has material basis in Ascomycota fungi that belong to a group called dermatophytes and has symptom itching in groin, thigh skin folds, or anus and results in formation of rash which appears as raised red plaques (platelike areas) and scaly patches with sharply defined borders that may blister and ooze.

MalaCards based summary: Tinea Cruris, also known as dermatophytosis of groin and perianal area, is related to dermatomycosis and dermatophytosis, and has symptoms including itching in groin An important gene associated with Tinea Cruris is SQLE (Squalene Epoxidase), and among its related pathways/superpathways is Defensins. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include groin, perineum and perianal region.

Wikipedia: 75 Tinea cruris, also known as jock itch, is a common type of contagious, superficial fungal infection of... more...

Related Diseases for Tinea Cruris

Diseases related to Tinea Cruris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 dermatomycosis 30.3 CYP51A1 CBS CARD9
2 dermatophytosis 30.2 SQLE RNASE7 DEFB4A CYP51A1 CLEC6A CBS
3 candidiasis 30.1 DEFB4A CYP51A1 CARD9
4 tinea corporis 29.9 TINAG SQLE RNASE7 DEFB4A CLEC6A CBS
5 tinea imbricata 29.9 TINAG DEFB104B DEFB104A CLEC6A CARD9
6 fungal infectious disease 29.8 DEFB4A CYP51A1 CLEC6A CBS CARD9
7 tinea pedis 29.5 SQLE RNASE7 DEFB4A CYP51A1 CLEC6A CBS
8 tinea manuum 29.5 TINAG TEF SQLE CBS CARD9
9 pityriasis versicolor 29.5 RNASE7 CLEC6A CBS CARD9
10 superficial mycosis 29.0 SQLE RNASE7 CLEC6A CBS CARD9
11 tinea unguium 28.8 TINAG TEF SQLE DEFB104B DEFB104A CYP51A1
12 contact dermatitis 10.3
13 allergic disease 10.2
14 skin disease 10.2
15 esophageal candidiasis 10.1 CYP51A1 CARD9
16 conidiobolomycosis 10.1 CYP51A1 CBS
17 middle lobe syndrome 10.1 DEFB104B DEFB104A
18 fusariosis 10.1 CYP51A1 CBS
19 mucormycosis 10.1 CYP51A1 CARD9
20 external ear disease 10.1 CYP51A1 CBS
21 otitis externa 10.1 CYP51A1 CBS
22 blue rubber bleb nevus 10.0
23 systemic lupus erythematosus 10.0
24 sarcoidosis 1 10.0
25 human immunodeficiency virus type 1 10.0
26 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.0
27 extrapulmonary tuberculosis 10.0
28 dermatitis 10.0
29 irritant dermatitis 10.0
30 granuloma annulare 10.0
31 erythrasma 10.0
32 secondary syphilis 10.0
33 syphilis 10.0
34 systemic scleroderma 10.0
35 tinea favosa 10.0
36 acquired immunodeficiency syndrome 10.0
37 gastrointestinal system disease 10.0
38 localized scleroderma 10.0
39 lupus erythematosus 10.0
40 tinea nigra 10.0
41 eczema herpeticum 10.0
42 candida glabrata 10.0
43 pityriasis rotunda 10.0
44 pustular psoriasis 10.0
45 antley-bixler syndrome 10.0 SQLE CYP51A1
46 trichosporonosis 10.0 CYP51A1 CBS CARD9
47 eumycotic mycetoma 10.0 CYP51A1 CBS CARD9
48 tinea profunda 10.0 CLEC6A CARD9
49 cutaneous candidiasis 10.0 CLEC6A CARD9
50 cryptococcal meningitis 9.9 CYP51A1 CLEC6A

Graphical network of the top 20 diseases related to Tinea Cruris:



Diseases related to Tinea Cruris

Symptoms & Phenotypes for Tinea Cruris

Symptoms:

11
  • itching in groin

Drugs & Therapeutics for Tinea Cruris

Drugs for Tinea Cruris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Luliconazole Approved Phase 4 187164-19-8 53394969 3003141
4
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
5 Anti-Infective Agents Phase 4
6 Antifungal Agents Phase 4
7 Gastrointestinal Agents Phase 4
8 Anti-Ulcer Agents Phase 4
9 Proton Pump Inhibitors Phase 4
10 Antacids Phase 4
11
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
12
Naftifine Approved Phase 3 65472-88-0 47641
13 Cytochrome P-450 Enzyme Inhibitors Phase 3
14 Cytochrome P-450 CYP3A Inhibitors Phase 3
15 Anti-Infective Agents, Local Phase 3
16 Hormones Phase 3
17 Hormone Antagonists Phase 3
18 Keratolytic Agents Phase 1

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
2 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
5 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
6 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
7 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
8 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
9 Clinical Study of Non-inferiority (Phase 2), Comparing Dapaconazole (BL123 - Biolab Sanus Farmacêutica Ltda.) Versus Miconazole Nitrate (União Química) in Patients With a Single Lesion of Tinea Cruris. Completed NCT03359070 Phase 2 Dapaconazole;Miconazole Nitrate
10 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
11 An Open Label, Parallel Group Comparison Study To Evaluate the Safety Tolerability, and Pharmacokinetics of UHE-103 Cream Versus Naftin Cream in Subjects With Tinea Cruris and/or Tinea Pedis Under Maximal Use Conditions Recruiting NCT05363449 Phase 1 UHE-103 Cream;Naftin (naftifine hydrochloride) Cream

Search NIH Clinical Center for Tinea Cruris

Genetic Tests for Tinea Cruris

Anatomical Context for Tinea Cruris

Organs/tissues related to Tinea Cruris:

FMA: Groin, Perineum, Perianal Region
MalaCards : Skin

Publications for Tinea Cruris

Articles related to Tinea Cruris:

(show top 50) (show all 405)
# Title Authors PMID Year
1
Genome-wide association study of dermatophytosis in the UK Biobank cohort. 62
35796184 2022
2
Profile of Nonvenereal Female Genital Dermatoses: A Cross-Sectional Study From Eastern India. 62
35763612 2022
3
Platyphylloside, a potential inhibitor from epicarp of B. aegyptiaca against CYP450 protein in T. rubrum - In vitro and in silico approaches. 62
35844431 2022
4
Clinicomycological Profile of Pediatric Dermatophytoses: An Observational Study. 62
36225993 2022
5
Changing face of epidemiology of dermatophytoses in Chinese Mainland: A 30 years nationwide retrospective study from 1991 to 2020. 62
35102623 2022
6
Update on dermatophytosis in Mashhad, Northeastern Iran, emergence of infection with Trichophyton persicum. 62
36092243 2022
7
Evaluating diagnostic utility of PAS stained skin scrape cytology smear in clinically suspected superficial cutaneous mycoses: A simple yet unpracticed technique. 62
35495809 2022
8
Prevalence and risk factors of vulvar dermatoses: A hospital-based study. 62
35846521 2022
9
Chronic Eczema Developing Over Skin Treated for Dermatophytosis in Atopic Patients -Importance of Treating Gently and Intelligently. 62
35656267 2022
10
A multicentric clinical and epidemiological study of chronic and recurrent dermatophytosis in India. 62
34378240 2022
11
Etiological prevalence and antifungal sensitivity patterns of dermatophytosis in India - A multicentric study. 62
34160163 2021
12
Oral Isotretinoin Combined with Oral Terbinafine Versus Oral Terbinafine Alone to Treat Recurrent Dermatophytosis: An Open-Label Randomised Clinical Trial. 62
34934716 2021
13
Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. 62
34760651 2021
14
Real World Analysis of Response Rate and Efficacy of Oral Ketoconazole in Patients with Recalcitrant Tinea Corporis and Cruris. 62
34634770 2021
15
Efficacy and Safety of Eberconazole vs Sertaconazole in Localised Tinea Infection. 62
35068526 2021
16
Clinico-Mycological Profile of Treatment-Naïve, Chronic, Recurrent and Steroid-Modified Dermatophytosis at a Tertiary Care Centre in Eastern India: An Institution-Based Cross-SectionalStudy. 62
34667758 2021
17
Prevalence of superficial-cutaneous fungal infections in Shiraz, Iran: A five-year retrospective study (2015-2019). 62
34028857 2021
18
Epidemiological study of terbinafine-resistant dermatophytes isolated from Japanese patients. 62
33439506 2021
19
Iatrogenic Cushing's Syndrome in Patients with Superficial Dermatophytosis. 62
33959519 2021
20
The influence of superficial dermatophytoses epidemic in India on patients' quality of life. 62
34408575 2021
21
An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India. 62
34611418 2021
22
Comparison of Success Rate and Complications of Totally Percutaneous Decannulation in Patients With Veno-Arterial Extracorporeal Membrane Oxygenation and Endovascular Aneurysm Repair. 62
34490310 2021
23
A Case of Terbinafine-Resistant Tinea Cruris Caused by Trichophyton tonsurans. 62
34925922 2021
24
Secondary syphilis mimicking tinea cruris in an HIV infected patient: a case report. 62
33912303 2021
25
Analysis on the pathogenic fungi in patients with superficial mycosis in the Northeastern China during 10 years. 62
33209125 2020
26
A curious observation of passive transfer of steroid antifungal combination creams to the scrotum in patients of tinea cruris-Is this forme fruste of red scrotum syndrome? 62
32829512 2020
27
Topical clotrimazole cream for the treatment of tinea cruris: A retrospective study. 62
33217827 2020
28
Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. 62
32538466 2020
29
A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth hormone deficiency and hyperthyroidism in a patient with pseudo-Turner's syndrome. 62
33045897 2020
30
Photodynamic therapy treatment of superficial fungal infections: A systematic review. 62
32339671 2020
31
Skin Barrier Function Defect - A Marker of Recalcitrant Tinea Infections. 62
32832443 2020
32
Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. 62
32898398 2020
33
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT). 62
32832435 2020
34
Psychosocial and Financial Impact of Disease among Patients of Dermatophytosis, a Questionnaire-Based Observational Study. 62
32695696 2020
35
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 62
31995350 2020
36
Prevalence and clinical characteristics of itch in epidemic-like scenario of dermatophytoses in India: a cross-sectional study. 62
31419346 2020
37
A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. 62
31491507 2019
38
Trichophyton mentagrophytes and T interdigitale genotypes are associated with particular geographic areas and clinical manifestations. 62
31444823 2019
39
Can Dermoscopy Serve as a Diagnostic Tool in Dermatophytosis? A Pilot Study. 62
31544071 2019
40
A Cross-Sectional Study on the Dermatoses in Postmenopausal Patients at a Rural-Based Tertiary Health Care Center. 62
31543529 2019
41
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 62
31321333 2019
42
A randomized, double-blind trial of amorolfine 0.25% cream and sertaconazole 2% cream in limited dermatophytosis. 62
30409926 2019
43
Dermatophytoses and spectrum of dermatophytes in patients attending a teaching hospital in Western Rajasthan, India. 62
31143732 2019
44
Risk factors for chronic and chronic-relapsing tinea corporis, tinea cruris and tinea faciei: Results of a case-control study. 62
30719987 2019
45
Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study. 62
31142947 2019
46
Dermatophytes in Skin, Nail and Hair among the Patients Attending Out Patient Department. 62
30739936 2019
47
Comparison of dapaconazole with miconazole in the treatment of Tinea cruris. 62
29888509 2019
48
2016 Epidemiological Survey of Dermatomycoses in Japan. 62
31474694 2019
49
Primary extramammary Paget's disease: a clinicopathological study of 28 cases. 62
31934186 2019
50
Potassium hydroxide mount with cellophane adhesive tape: a method for direct diagnosis of dermatophyte skin infections. 62
29845649 2018

Variations for Tinea Cruris

Expression for Tinea Cruris

Search GEO for disease gene expression data for Tinea Cruris.

Pathways for Tinea Cruris

Pathways related to Tinea Cruris according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.24 RNASE7 DEFB4A DEFB104B DEFB104A

GO Terms for Tinea Cruris

Biological processes related to Tinea Cruris according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.13 RNASE7 DEFB104B DEFB104A CLEC6A CARD9
2 defense response to bacterium GO:0042742 9.83 RNASE7 DEFB4A DEFB104B DEFB104A
3 positive chemotaxis GO:0050918 9.8 DEFB104A DEFB104B DEFB4A
4 positive regulation of T-helper 17 type immune response GO:2000318 9.76 CLEC6A CARD9
5 defense response to Gram-negative bacterium GO:0050829 9.76 RNASE7 DEFB4A DEFB104B DEFB104A
6 defense response to fungus GO:0050832 9.73 RNASE7 DEFB4A CLEC6A
7 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.71 DEFB104B DEFB104A
8 sterol biosynthetic process GO:0016126 9.69 SQLE CYP51A1
9 defense response GO:0006952 9.67 DEFB4A DEFB104B DEFB104A
10 disruption of membrane integrity in another organism GO:0051673 9.67 RNASE7 DEFB4A
11 antifungal innate immune response GO:0061760 9.43 DEFB4A CLEC6A CARD9
12 defense response to Gram-positive bacterium GO:0050830 9.32 RNASE7 DEFB4A DEFB104B DEFB104A CARD9

Molecular functions related to Tinea Cruris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.63 CYP51A1 CYP2A6 CBS
2 monooxygenase activity GO:0004497 9.26 SQLE CYP51A1 CYP2A6
3 chemoattractant activity GO:0042056 9.1 DEFB4A DEFB104B DEFB104A

Sources for Tinea Cruris

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....